PROF Earnings Prediction
The chart below shows how PROF performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PROF sees a -0.85% change in stock price 10 days leading up to the earnings, and a -3.73% change 10 days following the report. On the earnings day itself, the stock moves by +1.96%. This data can give you a slight idea of what to expect for the next quarter's release.
PROF Key Earning Data
PROF Earnings Analysis
Positive
Earnings Surprise Report: Profound Medical Corp. beats earnings expectations with a reported EPS of $-0.20, exceeding expectations of $-0.31.
Quarterly Revenue Surge: Fourth quarter 2024 revenue increased by 108% to $4.2 million compared to $2 million in the same period in 2023.
Gross Margin Improvement: Gross margin in Q4 2024 was 71%, a significant increase from 52% in Q4 2023.
Net Loss Improvement: The company recorded its lowest net loss since Q1 2020, with a net loss of $4.9 million, improving 45% from $8.9 million in Q4 2023.
Strong Cash Position: Profound ended the year with a strong cash position of $54.9 million.
Presentation Highlights on Prostate Treatment: TULSA-PRO was featured in 17 presentations at major society meetings, highlighting its precision and flexibility in treating prostate disease.
CAPTAIN Trial Progress: The CAPTAIN trial is on track, with 201 patients randomized and 174 treated or scheduled for treatment, marking a significant milestone in clinical trials for prostate cancer.
Capital Model Transition: The company has successfully transitioned to a capital model, enhancing its commercial strategy and positioning for growth.
Reimbursement Code Advantage: Profound's reimbursement codes are at a higher level than peers, applicable in a wider range of treatment settings, which supports broader adoption of TULSA.
Market Expansion Strategy: Plans for 2025 include the introduction of the BPH TULSA AI module, which could triple the total addressable market for TULSA from 200,000 to 600,000 patients per year.
Negative
Net Loss Despite Improvement: The company reported a net loss of $4.9 million in Q4 2024, despite a 45% improvement from the previous year, indicating ongoing financial challenges.
Operating Expenses Increase: Total operating expenses increased to $11.3 million in Q4 2024 from $9.8 million in Q4 2023, suggesting rising costs that may impact profitability.
Revenue Growth Concerns: While revenue increased by 108% year-over-year, the total revenue of $4.2 million is still relatively low, raising concerns about the company's ability to scale effectively.
TULSA Technology Commercialization Challenges: The company is still in the early stages of commercializing its TULSA technology, which may lead to uncertainties in market adoption and revenue generation.
Ongoing Net Losses: Despite improvements, the company has not yet achieved profitability, as indicated by the continued net losses reported in the earnings call.
PROF FAQs
How does PROF typically perform around its earnings report dates?
PROF's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a -0.84% change leading up to the report and a -3.73% change in the 10 days following the release.
Is Profound Medical Corp (PROF) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PROF Earning Call Sentiment
Profound Medical Corp. (NASDAQ:PROF) Q4 2024 Earnings Call Transcript
PROF.O
-6.89%
